James Rolke's most recent trade in Revelation Biosciences Inc was a trade of 8,521 Common Stock done at an average price of $1.9 . Disclosure was reported to the exchange on Feb. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revelation Biosciences Inc | James Rolke | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.86 per share. | 03 Feb 2026 | 8,521 | 224,853 | - | 1.9 | 15,849 | Common Stock |
| Revelation Biosciences Inc | James Rolke | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.90 per share. | 08 Jan 2026 | 532,829 | 933,489 | - | 0.9 | 479,546 | Common Stock |
| Revelation Biosciences Inc | James Rolke | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 1.28 per share. | 29 Oct 2025 | 390,614 | 400,660 | - | 1.3 | 499,986 | Common Stock |
| Revelation Biosciences Inc | James Rolke | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 3.87 per share. | 11 Feb 2025 | 30,095 | 30,137 | - | 3.9 | 116,468 | Common Stock |
| Revelation Biosciences Inc | James Rolke | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 2,542 | 0 | - | - | Stock Option (Right to Buy) |